|
Home
|
E-Submission
|
Sitemap
|
Contact Us
|
About KJIM
Aims and Scope
Editorial Board
Subscriptions
Open Access
Contact us
E-Submission
Instructions for Authors
Checklist
Instructions for Reviewers
Article-processing Charge
Ahead of Print
Current Issue
Archive
Most Read Articles
Most Cited Articles
KJIM Search
Author Index
Gastroenterology
Cardiology
Pulmonology
Endocrinology-metabolism
Nephrology
Hemato-oncology
Infectious diseases
Allergy
Rheumatology
Korean J Intern Med Search
> Browse Articles > Korean J Intern Med Search
Loeffler endocarditis in chronic eosinophilic leukemia with FIP1L1/PDGFRA rearrangement: full recovery with low dose imatinib
Dae Sik Kim, Sunki Lee, Chul Won Choi
Korean J Intern Med.
2018;33(3):642-644. Published online June 28, 2017
DOI:
https://doi.org/10.3904/kjim.2016.100
Hemato-oncology
Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications
Junghoon Shin, Youngil Koh, Jeonghwan Youk, Miso Kim, Byung Soo Kim, Chul Won Choi, Hwa Jung Sung, Yong Park, Sung-Soo Yoon, Inho Kim
Korean J Intern Med.
2017;32(4):722-730. Published online June 26, 2017
DOI:
https://doi.org/10.3904/kjim.2016.256
Cited By 1
Background/Aims: Although multiple myeloma (MM) is typically a disease of the elderly, a certain subset of extremely young patients exists. It is necessary to establish clinicopathological characteristics for this population. Methods: We reviewed the medical records of MM patients whose age was 40 ..
Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma
Dae Sik Kim, Eun Sang Yu, Ka-Won Kang, Se Ryeon Lee, Yong Park, Hwa Jung Sung, Chul Won Choi, Byung Soo Kim
Korean J Intern Med.
2017;32(4):711-721. Published online November 4, 2016
DOI:
https://doi.org/10.3904/kjim.2016.054
Cited By 2
Background/Aims: The aims of this study were to identify the value of inflammatory markers as pretreatment prognostic factors for patients with multiple myeloma (MM) and to estimate the value of a prognostic index including these markers at diagnosis. Methods: A total of 273 newly diagnosed MM pati..
Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells
Dae Sik Kim, Yoo Jin Na, Myoung Hee Kang, Soo-Young Yoon, Chul Won Choi
Korean J Intern Med.
2016;31(2):357-366. Published online February 15, 2016
DOI:
https://doi.org/10.3904/kjim.2015.024
Cited By 3
Background/Aims: The treatment of chronic myeloid leukemia (CML) has achieved impressive success since the development of the Bcr-Abl tyrosine kinase inhibitor, imatinib mesylate. Nevertheless, resistance to imatinib has been observed, and a substantial number of patients need alternative treatment ..
Guidelines for the management of myeloproliferative neoplasms
Chul Won Choi, Soo-Mee Bang, Seongsoo Jang, Chul Won Jung, Hee-Jin Kim, Ho Young Kim, Soo-Jeong Kim, Yeo-Kyeoung Kim, Jinny Park, Jong-Ho Won
Korean J Intern Med.
2015;30(6):771-788. Published online October 30, 2015
DOI:
https://doi.org/10.3904/kjim.2015.30.6.771
Cited By 7
Polycythemia vera, essential thrombocythemia, and primary myelofibrosis are collectively known as ‘Philadelphia-negative classical myeloproliferative neoplasms (MPNs).’ The discovery of new genetic aberrations such as Janus kinase 2 (
JAK2
) have enhanced our understanding of the pathophysio..
Clinical characteristics, pathological distribution, and prognostic factors in non-Hodgkin lymphoma of Waldeyer’s ring: nationwide Korean study
Seong Jun Lee, Cheol Won Suh, Soon Il Lee, Won Seog Kim, Won Sik Lee, Hyo Jung Kim, Chul Won Choi, Jin Seok Kim, Jin Seok Kim, Ho-Jin Shin, Ho-Jin Shin, The Consortium for Improving Survival of Lymphoma , The Consortium for Improving Survival of Lymphoma
Korean J Intern Med.
2014;29(3):352-360. Published online April 29, 2014
DOI:
https://doi.org/10.3904/kjim.2014.29.3.352
Cited By 12
Background/Aims:
In Asia, the incidence of non-Hodgkin lymphoma (NHL) has increased in recent decades. Waldeyer’s ring (WR) is the most common site of NHL involving the head and neck. In this study, the pathological distribution of WR-NHL and its clinical features were analyzed retrospectiv..
Unusual Presentation of Thymic Carcinoma : Hypertrophic Osteoarthropathy
Seok Jin Kim, Jae Hong Seo, Chul won Choi, Eung Seok Lee, Bo Kyoung Seo, and Jun Suk Kim
Korean J Intern Med.
2003;18(2):125-128. Published online June 1, 2003
DOI:
https://doi.org/10.3904/kjim.2003.18.2.125
Cited By 2
Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
Se Ryeon Lee, Hojoon Choi, Byung Hyun Lee, Ka-Won Kang, Eun Sang Yu, Dae Sik Kim, Yong Park, Chul Won Choi, Byung Soo Kim, Hwa Jung Sung
Received April 18, 2018 Accepted May 9, 2018 Published online October 26, 2018
DOI:
https://doi.org/10.3904/kjim.2018.144
[Epub ahead of print]
Background/Aims: Bortezomib plus melphalan-prednisone (VMP) is a standard treatment for multiple myeloma, particularly for patients who are ineligible for high-dose therapy. However, early discontinuation or treatment modification is often needed owing to adverse events. The aim of this study was to..
1
> Browse Articles > Korean J Intern Med Search
